

FILE 'HOME' ENTERED AT 15:52:37 ON 13 JUL 2006

=> b caplus biosis scisearch medline

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
1.47	1.47

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:56:55 ON 13 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:56:55 ON 13 JUL 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 15:56:55 ON 13 JUL 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 15:56:55 ON 13 JUL 2006

=> s treatment and drug and conversion

L1 12882 TREATMENT AND DRUG AND CONVERSION

=> s l1 and treatment (P) conversion

L2 11147 L1 AND TREATMENT(P) CONVERSION

=> s l2 and octreotide and pegvisomant

L3 3 L2 AND OCTREOTIDE AND PEGVISOMANT

=> dup remo l3

PROCESSING COMPLETED FOR L3

L4 2 DUP REMO L3 (1 DUPLICATE REMOVED)

=> d 14 1-2 bib abs

L4 ANSWER 1 OF 2 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 1

AN 2005:468947 BIOSIS

DN PREV200510254072

TI Glucose homeostasis and safety in patients with acromegaly converted from  
long-acting octreotide to pegvisomant.

AU Barkan, Ariel L. [Reprint Author]; Burman, Pia; Clemons, David R.; Drake,  
William M.; Gagel, Robert F.; Harris, Philip E.; Trainer, Peter J.; van  
der Lely, Aart Jan; Vance, Mary Lee

CS Univ Michigan, Med Ctr, Dept Internal Med, 3920 Taubman Ctr, Ann Arbor, MI  
48109 USA

abarkan@med.umich.edu

SO Journal of Clinical Endocrinology & Metabolism, (OCT 2005) Vol. 90, No.  
10, pp. 5684-5691.

CODEN: JCEMAZ. ISSN: 0021-972X.

DT Article

LA English

ED Entered STN: 9 Nov 2005

Last Updated on STN: 9 Nov 2005

AB Context: In clinical practice, patients with acromegaly may be switched  
from therapy with long-acting somatostatin analogs to pegvisomant

. The effect of changing therapies on glucose homeostasis and safety has  
not been reported.Objectives: The objectives of this study were to monitor  
changes in IGF-I levels, glycemic control, and safety, particularly liver  
function and tumor size.Design: This was a multicenter, open-label, 32-wk  
trial study.Setting: The study was performed at outpatient  
clinics.Patients: Fifty-three patients with acromegaly previously treated  
with octreotide long-acting release (LAR) participated in this

study. Intervention: Pegvisomant (10 mg/d) was initiated 4 wk after the last dose of octreotide LAR and was adjusted based on serum IGF-I concentrations at wk 12, 20, and 28. Main Outcome Measures: The main outcome measures were changes in IGF-I, glycosylated hemoglobin A(1c) (HbA(1c)), fasting plasma glucose, and safety during the first 12 wk after conversion. Results: At the end of pegvisomant treatment, IGF-I was normalized in 78% of patients. At wk 32, median fasting glucose concentration and HbA(1c) were reduced (-1.4 mmol/liter and -0.4%, respectively; both  $P \leq 0.0001$ ) in the study population. Improvements in glycemic control occurred in patients with normal IGF-I concentrations at wk 4 [n = 15; fasting glucose, -1.7 mmol/liter ( $P \leq 0.0001$ ); HbA(1c) -0.2% ( $P = 0.03$ )]. Decreases in fasting glucose and HbA(1c) levels were observed in patients with and without diabetes. HbA(1c) was reduced by more than 1.0% in patients with diabetes. Median pituitary tumor volume did not change, although tumor volume increased in two patients with macroadenomas. Conclusions: Conversion from octreotide LAR to pegvisomant was safe and well tolerated. Improved glycemic control indicates that pegvisomant should be considered in patients with acromegaly and diabetes.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:927079 CAPLUS  
 DN 141:360723  
 TI Growth hormone receptor antagonist-COX-2 inhibitor combination with antihypertension agents for use in treatment of patients with acromegaly  
 IN Fryklund, Linda; Harris, Philip  
 PA Pharmacia & Upjohn Company, USA  
 SO PCT Int. Appl., 54 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093913	A1	20041104	WO 2004-GB1771	20040426
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI GB 2003-9328 A 20030424  
 AB The invention provides a method for the treatment of hypertension in a patient characterized by using a growth hormone receptor antagonist in combination with an antihypertension agent.  
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>  
 => d his

(FILE 'HOME' ENTERED AT 15:52:37 ON 13 JUL 2006)

FILE 'CAPLUS, BIOSIS, SCISEARCH, MEDLINE' ENTERED AT 15:56:55 ON 13 JUL 2006

L1 12882 S TREATMENT AND DRUG AND CONVERSION

L2 11147 S L1 AND TREATMENT(P) CONVERSION  
L3 3 S L2 AND OCTREOTIDE AND PEGVISOMANT  
L4 2 DUP REMO L3 (1 DUPLICATE REMOVED)

## WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)

DATE: Thursday, July 13, 2006

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L4	treatment same drug same conversion same overlap	3
<input type="checkbox"/>	L3	octreotide and L2	14
<input type="checkbox"/>	L2	pegvisomant and acromeg\$	26
<input type="checkbox"/>	L1	pegvisomant.clm.	9

END OF SEARCH HISTORY